Genprex rises after winning US patent for cancer drug combination

Genprex

18/11/2025 12:27

** Shares of drug developer Genprex GNPX.O rise 12.13% to $4.53 premarket

** Company says it has received a U.S. patent for its experimental gene therapy Reqorsa when used with a type of cancer immunotherapy called PD-L1 antibodies, including Roche's ROG.S Tecentriq, to treat cancer

** The patent, which runs through 2037, gives GNPX exclusive rights to the drug combination and covers its ongoing early-to-mid stage trial for small cell lung cancer

** PD-L1 antibodies help immune system attack cancer by blocking checkpoint proteins

** The trial is testing Reqorsa along with Tecentriq as maintenance therapy in patients with extensive-stage small cell lung cancer

** Up to last close, shares down ~91% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))